Transcardiac increase in norepinephrine and prognosis in patients with chronic heart failure

European Journal of Heart Failure

Volumn 10, Issue 12, 2008, Pages 1208-1214

  Tsutamoto, Takayoshi ^a   Nishiyama, Keizo ^a   Sakai, Hiroshi ^a   Tanaka, Toshinari ^a   Fujii, Masanori ^a   Yamamoto, Takashi ^a   Yamaji, Masayuki ^a   Horie, Minoru ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

123I metaiodobenzylguanidine; N terminal pro brain natriuretic peptide; Norepinephrine; Prognosis; Sympathetic nervous activity

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; NEUROHORMONE; NORADRENALIN;

ADULT; AORTA ROOT; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; CORONARY SINUS; CORRELATION ANALYSIS; FEMALE; FOLLOW UP; HEART FAILURE; HEMODYNAMICS; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NORADRENALIN BLOOD LEVEL; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS;

BIOLOGICAL MARKERS; CHRONIC DISEASE; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; NOREPINEPHRINE; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RENAL DIALYSIS; SYMPATHETIC NERVOUS SYSTEM; TIME FACTORS;

EID: 56349086502     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejheart.2008.09.011     Document Type: Article

References (33)

1. Cohn J.N., Levine T.B., Olivari M.T., et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 311 13 (1984) 819-823
2. Anand I.S., Fisher L.D., Chiang Y.T., et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 107 9 (2003) 1278-1283
3. Latini R., Masson S., Anand I., et al. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J 25 4 (2004) 292-299
4. Swedberg K., Viquerat C., Rouleau J.L., et al. Comparison of myocardial catecholamine balance in chronic congestive heart failure and in angina pectoris without failure. Am J Cardiol 54 7 (1984) 783-786
5. Kaye D.M., Lefkovits J., Jennings G.L., Bergin P., Broughton A., and Esler M.D. Adverse consequences of high sympathetic nervous activity in the failing human heart. J Am Coll Cardiol 26 5 (1995) 1257-1263
6. Chidsey C.A., Braunwald E., and Morrow A.G. Catecholamine excretion and cardiac stores of norepinephrine in congestive heart failure. Am J Med 39 (1965) 442-451
7. Hasking G.J., Esler M.D., Jennings G.L., Burton D., Johns J.A., and Korner P.I. Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation 73 4 (1986) 615-621
8. Eisenhofer G., Friberg P., Rundqvist B., et al. Cardiac sympathetic nerve function in congestive heart failure. Circulation 93 9 (1996) 1667-1676
9. Merlet P., Dubois-Rande J.L., Adnot S., et al. Myocardial beta-adrenergic desensitization and neuronal norepinephrine uptake function in idiopathic dilated cardiomyopathy. J Cardiovasc Pharmacol 19 1 (1992) 10-16
10. Rabinovitch M.A., Rose C.P., Rouleau J.L., et al. Metaiodobenzylguanidine [131I] scintigraphy detects impaired myocardial sympathetic neuronal transport function of canine mechanical-overload heart failure. Circ Res 61 6 (1987) 797-804
11. Simmons W.W., Freeman M.R., Grima E.A., Hsia T.W., and Armstrong P.W. Abnormalities of cardiac sympathetic function in pacing-induced heart failure as assessed by [123I]metaiodobenzylguanidine scintigraphy. Circulation 89 6 (1994) 2843-2851
12. Schofer J., Spielmann R., Schuchert A., Weber K., and Schluter M. Iodine-123 meta-iodobenzylguanidine scintigraphy: a noninvasive method to demonstrate myocardial adrenergic nervous system disintegrity in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 12 5 (1988) 1252-1258
13. Henderson E.B., Kahn J.K., Corbett J.R., et al. Abnormal I-123 metaiodobenzylguanidine myocardial washout and distribution may reflect myocardial adrenergic derangement in patients with congestive cardiomyopathy. Circulation 78 5 Pt 1 (1988) 1192-1199
14. Merlet P., Valette H., Dubois-Rande J.L., et al. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med 33 4 (1992) 471-477
15. Merlet P., Benvenuti C., Moyse D., et al. Prognostic value of MIBG imaging in idiopathic dilated cardiomyopathy. J Nucl Med 40 6 (1999) 917-923
16. Matsui T., Tsutamoto T., Maeda K., Kusukawa J., and Kinoshita M. Prognostic value of repeated 123I-metaiodobenzylguanidine imaging in patients with dilated cardiomyopathy with congestive heart failure before and after optimized treatments-comparison with neurohumoral factors. Circ J 66 6 (2002) 537-543
17. Verberne H.J., Brewster L.M., Somsen G.A., and van Eck-Smit B.L. Prognostic value of myocardial 123I-metaiodobenzylguanidine (MIBG) parameters in patients with heart failure: a systematic review. Eur Heart J 29 9 (2008) 1147-1159
18. Matsui T., Tsutamoto T., and Kinoshita M. Relationship between cardiac 123I-metaiodobenzylguanidine imaging and the transcardiac gradient of neurohumoral factors in patients with dilated cardiomyopathy. Jpn Circ J 65 12 (2001) 1041-1046
19. Gilbert E.M., Abraham W.T., Olsen S., et al. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation 94 11 (1996) 2817-2825
20. Tsutamoto T., Wada A., Maeda K., et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 96 2 (1997) 509-516
21. Maeda K., Tsutamoto T., Wada A., Hisagawa T., and Kinoshita M. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 135 5 Pt 1 (1998) 825-832
22. Maeda K., Tsutamoto T., Wada A., et al. High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol 36 5 (2000) 1587-1593
23. Richards A.M., Doughty R., Nicholls M.G., et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. J Am Coll Cardiol 37 7 (2001) 1781-1787
24. Tsutamoto T., Wada A., Sakai H., et al. Relationship between renal function and plasma brain natriuretic peptide in patients with heart failure. J Am Coll Cardiol 47 3 (2006) 582-586
25. Tsutamoto T., Sakai H., Ishikawa C., et al. Direct comparison of transcardiac difference between brain natriuretic peptide (BNP) and N-terminal pro-BNP in patients with chronic heart failure. Eur J Heart Fail 9 6-7 (2007) 667-673
26. Imamura Y., Fukuyama T., Mochizuki T., Miyagawa M., and Watanabe K. Prognostic value of iodine-123-metaiodobenzylguanidine imaging and cardiac natriuretic peptide levels in patients with left ventricular dysfunction resulting from cardiomyopathy. Jpn Circ J 65 3 (2001) 155-160
27. Kyuma M., Nakata T., Hashimoto A., et al. Incremental prognostic implications of brain natriuretic peptide, cardiac sympathetic nerve innervation, and noncardiac disorders in patients with heart failure. J Nucl Med 45 2 (2004) 155-163
28. Poole-Wilson P.A., Swedberg K., Cleland J.G., et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 362 9377 (2003) 7-13
29. Abraham W.T., Fisher W.G., Smith A.L., et al. Cardiac resynchronization in chronic heart failure. N Engl J Med 346 24 (2002) 1845-1853
30. Burri H., Sunthorn H., Somsen A., et al. Improvement in cardiac sympathetic nerve activity in responders to resynchronization therapy. Europace 10 3 (2008) 374-378
31. Tsutamoto T., Sakai H., Nishiyama K., et al. Direct comparison of transcardiac increase in brain natriuretic peptide (BNP) and N-terminal proBNP and prognosis in patients with chronic heart failure. Circ J 71 12 (2007) 1873-1878
32. Esler M., Jennings G., Lambert G., Meredith I., Horne M., and Eisenhofer G. Overflow of catecholamine neurotransmitters to the circulation: source, fate, and functions. Physiol Rev 70 4 (1990) 963-985
33. Akiyama T., Yamazaki T., and Ninomiya I. In vivo monitoring of myocardial interstitial norepinephrine by dialysis technique. Am J Physiol 261 5 Pt 2 (1991) H1643-1647